FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549	

<b>STATEMENT</b>	OF CHANGES	S IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average	burden										
hours per response	: 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GRAHAM RICHARD A</u>					2. Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [ TBPH ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify						
(Last)	`	rst) (M E BIOPHARMA	Middle)	NC.	3. Date of Earliest Transaction (Month/Day/Year) 02/20/2024								X SV	belov		& DE	below)		
· · · · · · · · · · · · · · · · · · ·					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person						
(Street) SOUTH FRANCI		A 9	4080											X		filed by Mo		Ü	
(City)	(St	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - No	n-Deriva	tive S	Secur	ities	Acq	uired,	Dis	posed of	or B	enefi	cially	<b>Own</b>	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Date)			Execution Date,		Date,	Transaction Disposed Code (Instr. 5)		es Acquired (A) Of (D) (Instr. 3,			5. Amount of Securities Beneficially Owned Following				7. Nature of Indirect Beneficial Ownership				
										v	Amount	(A) (D)	or Pri	ce	Transa	eported ransaction(s) nstr. 3 and 4)			(Instr. 4)
Ordinary	nary Shares 02/20/2			024 F 19,294 <sup>(1)</sup> D			\$	\$8.92 314,915 D											
		Tal									osed of, o				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	Transaction of I		Expirat	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price Derivati Security (Instr. 5)		tive derivative ity Securities	y Direct or Inc (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market

/s/ Brett A. Grimaud, Attorney-in-Fact

\*\* Signature of Reporting Person Date

02/22/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.